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A five-month-old female Jack Russell terrier was presented for investigation of acute 
lethargy, anorexia, coughing, respiratory distress and weakness. Examination findings 
included cyanosis, a grade 3 of 6 systolic heart murmur and prolonged capillary refill time. 
Radiography and echocardiography revealed severe pulmonary hypertension, cor pulmonale 
and right-sided heart failure. Indirect measurement of the systolic pulmonary artery pressure 
estimated pressures over 100 mmHg. Despite treatment the patient died. Post-mortem 
examination did not identify a congenital cardiovascular anomaly. Histopathology confirmed 
acute necrotising pulmonary arteritis and immunohistochemistry failed to identify any 







Vasculitis is a pathological process characterised by inflammation and necrosis of blood 
vessels. Vessels of any type and virtually any organ system may be affected and hence may 
lead to a multitude of clinical manifestations and syndromes. Acute necrotising vasculitis 
affecting the pulmonary vasculature exclusively has been rarely reported in dogs. Kolm and 
others (2004), Gavaghan and others (1998) and Turk and others (1981) each described a 
single case of acute necrotising pulmonary vasculitis in immature dogs with patent ductus 
arteriosus (PDA). Turk and others (1984) also described a case of acute necrotising 
pulmonary vasculitis in a young miniature schnauzer with peritoneopericardial hernia. All 
these case reports described histopathological evidence of acute necrotising pulmonary 
vasculitis with circumferential myointimal thickening. Each patient developed severe 
pulmonary arterial hypertension (PAH), right-sided heart failure and died or was euthanased 
because of progression of clinical signs. Gavaghan and others (1998) proposed that in 
circumstances of pulmonary vascular dysfunction, a relatively transient or mild hypoxic, 
metabolic, inflammatory or flow-related insult may serve as a catalyst for self-perpetuating 
progressive pulmonary hypertension. 
 
Pulmonary arteritis in human patients with medial hypertrophy and fibrosis is associated with 
a poor clinical prognosis. A variety of mechanisms have been proposed to cause pulmonary 
vascular dysfunction in people. Increased endothelin-1, reduced nitric oxide-mediated 
vasodilation, pulmonary hypoxaemia and imbalances of endothelin-1 receptor subpopulations 
associated with the increased pulmonary blood flow contribute to impairment of normal 
physiological vascular responses (Wong and others 1995). This case report describes severe acute necrotising pulmonary panarteritis that caused 
terminal PAH in an immature Jack Russell terrier. To the authors’ knowledge, acute 
necrotising vasculitis affecting the pulmonary vasculature alone has not been described in 




A five-month-old female Jack Russell terrier, weighing 5·8 kg, was presented with acute 
lethargy, anorexia and coughing of five days’ duration. Over the preceding two months, the 
patient had presented to the referring veterinarian on several occasions with dysuria and 
pigmenturia. Urinalysis results included pyuria, proteinuria and bacteriuria consistent with 
urinary tract infection (UTI). Aerobic urine culture yielded a pure heavy growth of non-
haemolytic Escherichia coli sensitive to β-lactams, trimethoprim-sulphonamides, 
fluoroquinolones, aminoglycosides and tetracyclines. Initially, 20 mg/kg amoxicillin-
clavulanate was administered orally twice daily for two weeks and the clinical signs were 
resolved. When clinical signs recurred within two days of therapy completion, a course of 20 
mg/kg cephalexin twice daily was administered for five weeks. The dog was referred five 
days after completion of antibiotics. 
 
The dog was presented to the emergency service of Murdoch University Veterinary Hospital. 
Physical examination showed generalised weakness, collapse, cyanosis, tachypnoea, 
prolonged capillary refill, weak irregular femoral pulses, jugular distension and pulses, 
hepatomegaly, severe tachycardia (heart rate 250 beats per minute) and a (grade 3 of 6) 
systolic heart murmur with point of maximal intensity over the right cardiac apex. These findings were consistent with right-sided heart failure and poor peripheral perfusion. 
Investigation included evaluation of pulse oximetry, systemic blood pressures, haematology, 
biochemistry, thoracic radiography, electrocardiography (ECG) and echocardiography. 
Systemic arterial blood pressures (systolic), measured by indirect Doppler 
sphygmomanometry, varied between 90 and 110 mmHg and pulse oximetry estimated 
oxygen-haemoglobin saturation at 60 to 70 per cent on presentation and 80 to 85 per cent 
with oxygen supplementation. 
 
Thoracic radiographs (Fig 1) showed marked right-sided enlargement of the cardiac 
silhouette, a pulmonary hypervascular pattern because of dilation of the pulmonary arteries 
and mild pulmonary hyperinflation. 
 
ECG (Fig 2) findings included supraventricular tachyarrhythmia (sinus tachycardia or 
supraventricular tachycardia [SVT]), deep S waves in leads I, II and aVF, tall R waves in lead 
III and right axis deviation of the mean electrical axis in the frontal plane, consistent with 
right ventricular enlargement or hypertrophy. Vagal manoeuvres did not alter the heart rate or 
rhythm. 
 
Echocardiography (Fig 3) showed marked dilatation of the right ventricle and atrium, 
hypertrophy of the right ventricular free wall, marked enlargement of the main pulmonary 
artery, marked pulmonary regurgitation (Vmax=4·0 m/s) and severe tricuspid insufficiency 
(Vmax=5·05 m/s). The left atrial, left ventricular and aortic dimensions were markedly 
reduced, consistent with left-sided volume depletion. The fractional shortening was elevated (62 per cent, reference 29 to 45 per cent). Hepatic vein dilation was noted on abdominal 
ultrasound. Two-dimensional and Doppler echocardiography including cephalic vein bubble 
studies did not identify anomalous vasculature or a shunt. 
 
Complete blood count and serum biochemistry results included mild mature neutrophilia 
(12·8×10
9/l, reference 3 to 11·5×10
9/l), monocytosis (1·58×10
9/l, reference 0·35 to 
1·35×10
9/l), azotaemia (urea 13·1 mmol/l, reference 3·6 to 10 mmol/l), hyperphosphataemia 
(2·67 mmol/l, reference 0·8 to 2·2 mmol/l), increased creatine kinase (269 U/l) and 
hypoproteinaemia (52 g/l, reference 56 to 80 g/l) because of hypoglobulinaemia (globulins 23 
g/l, reference 28 to 44 g/l). 
 
Assessment and treatment 
 
The most prominent clinical problems were pulmonary hypertension, hypoxaemia and right 
heart failure. These were considered most likely because of an unidentified congenital left-to-
right vascular shunt. Treatment included humidified nasal oxygen supplementation (200 
ml/kg/minute), anxiolytics (0·05 mg/kg morphine intramuscularly), intravenous 1 mg/kg 
frusemide and an intravenous bolus of 0·05 mg/kg verapamil followed by constant rate 
infusion at 2 μg/kg/minute. The heart rate decreased in response to treatment; however, the 
patient’s clinical condition continued to deteriorate and progressed to respiratory arrest and 
death within 12 hours of presentation. 
 Post-mortem examination 
A large amount of intraluminal tracheobronchial (stable) froth and abnormal diffuse multi-
focal coalescing pulmonary congestion were present. Cardiovascular findings included severe 
right heart dilation, marked right ventricular hypertrophy and an interventricular septal bulge 
into the left ventricle. The great vessels and other body systems grossly appeared normal. 
The most prominent histopathological changes were in the lung (Fig 4) including a diffuse 
increase in alveolar macrophages accompanied by prominent multi-focal alveolar fibrin 
exudate, alveolar oedema and lymphatic dilation. Panarteritis with nuclear dust and fibrinoid 
necrosis affected the small- to medium-sized pulmonary arteries. Abundant alveolar fibrin 
and widespread fibrinoid necrosis in arteries of various diameters were demonstrated by 
Martius scarlet blue staining. Hepatic sections exhibited periacinar zonal congestion and mild 
hepatocellular necrosis. The kidneys, urinary bladder, adrenal glands, thyroid, heart and brain 
appeared histologically normal. The post-mortem diagnosis of acute necrotising pulmonary 
panarteritis and acute fibrinous pneumonia supported the clinical findings of pulmonary 




In human medicine, vasculitides are well described and their classification is based on the 
pathogenic mechanisms, the anatomical site and histological characteristics of the lesions, 
together with their clinical manifestations (Schoen and Cotran 1999). Heath and Edwards 
(1958) originally proposed a histopathological classification of pulmonary vasculopathy 
describing progressive degrees of pulmonary artery myointimal proliferation, vascular occlusion, fibrosis, inflammation and necrosis on a graded (I-VI) scale that provided a 
framework for future study and a guide for prognosis. In contrast, vascular disease in animals 
is relatively poorly documented, and the underlying aetiology in most cases is unknown (Fox 
and others 2005). Regardless of the underlying cause, the inflammatory process may become 
chronic and result in progressive intimal thickening and irreversible fibrosis of the affected 
vessels. 
 
The signs of vasculitis vary considerably depending on the organ system(s) affected. 
Reported clinical syndromes in animals involve the skin (Keenan and others 1977, Scott and 
others 1978, Wilcock and Yager 1986), central nervous system (Kelly and others 1973, Meric 
and others 1986, Carpenter and others 1988, Scott-Moncrieff and others 1992, Snyder and 
others 1995, Caswell and Nykamp 2003) and joints (Lewis and Borel 1971). To the authors’ 
knowledge, there are only five clinical reports of dogs with acute necrotising pulmonary 
vasculitis in the veterinary literature. Three dogs had PDA (Turk and others 1981, Gavaghan 
and others 1998, Kolm and others 2004), one dog had a peritoneopericardial diaphragmatic 
hernia (Turk and others 1984) and another had visceral leishmaniasis (Pumarola and others 
1991). Exercise intolerance, dyspnoea and cyanosis with, or without, right heart failure were 
the most common clinical signs. All dogs had a heart murmur and one dog with a PDA was 
asymptomatic at initial presentation (Gavaghan and others 1998). Similarly, people with 
pulmonary vasculitis and PAH may be asymptomatic or have varying degrees of exercise 
intolerance, fatigue, angina, near-syncope, dyspnoea or right heart failure (Humbert and 
others 2004). 
 Pulmonary vasculitis typically results in PAH, its severity being inversely related to the total 
cross-sectional area of the vascular bed (Goldstein 1985). Chronic pulmonary hypertension 
leads to a self-perpetuating process of vascular medial hypertrophy and intimal proliferation 
(Goldstein 1985). Persistent, progressive PAH causes increased right ventricular afterload 
and wall stress, leading to right ventricular hypertrophy and dilation. The subsequent 
decrease in cardiac index may result in clinical signs of right-sided heart failure, as was the 
case in the dog described in this report. 
 
Clinically, a variety of causes of PAH are recognised in human beings and animals. These 
include increased pulmonary blood flow (left-to-right shunts), dirofilariasis (heartworm 
disease), pulmonary vascular dysfunction, increased left atrial pressure, chronic obstructive 
or interstitial pulmonary disease, hypoxaemia, metabolic acidosis and pulmonary 
thromboembolism (Perry and others 1991, Humbert and others 2004). The diagnostic 
evaluation of a patient with suspected PAH may include assessment of history, physical 
examination, haematology, biochemistry, urinalysis, heartworm status, coagulation studies, 
blood gas analysis, thoracic radiography, ECG, echocardiography, pulmonary perfusion 
scintigraphy and thoracic computed tomography. Bronchoscopy, bronchoalveolar lavage, 
cytology and culture may aid diagnosis if primary bronchopulmonary disease is suspected. In 
this case, heartworm antigen testing was not performed because of the patient’s age. 
Dirofilariasis was therefore considered unlikely and post-mortem examination ruled it out. 
Unfortunately, urine and blood cultures were not performed. Sepsis or endotoxaemia 
secondary to ascending UTI, or resulting in UTI, may have the potential to cause vasculitis. 
However, post-mortem and histological examination of the kidneys did not show any 
evidence of pyelonephritis or septicaemia. Blood gas analysis may have added further information regarding the patient’s arterial oxygen tension and acid-base status; yet, none of 
these measures were likely to have changed the treatment plan or outcome. 
 
The antemortem diagnosis of pulmonary vasculitis remains a challenge for the clinician as it 
requires histopathological assessment, and lung biopsy is often not feasible in the living 
patient. However, if a definitive cause of pulmonary hypertension cannot be made on the 
basis of the testing described above, a tentative diagnosis of pulmonary vasculitis should be 
considered. Infectious disease including dirofilariasis, angiostrongylosis, leishmaniasis, 
ehrlichiosis, Rocky Mountain spotted fever, bartonellosis, borreliosis, sepsis and 
hepatozoonosis should be ruled out in their respective endemic areas if pulmonary vasculitis 
is suspected. 
 
Echocardiographic changes accompanying PAH include right ventricular dilation, right 
ventricular hypertrophy, tricuspid insufficiency, paradoxical septal motion, enlarged 
pulmonary artery, decreased left ventricular chamber dimension, prolapse of the tricuspid and 
pulmonic valves and increased left ventricular wall and septal thicknesses (Lombard and 
Buergelt 1983, Atkins and others 1988, Badertscher and others 1988). In addition, a reduced 
pulmonary artery acceleration time-to-ejection time ratio may be present in patients with 
PAH and without tricuspid or pulmonic insufficiency (Schober and Baade 2006). Using the 
modified Bernoulli equation in this case study, the peak velocity of tricuspid regurgitation 
(Vmax=5·05 m/s) corresponded to a transtricuspid valve pressure gradient of 102 mmHg. As 
the patient was in right heart failure, the right atrial pressure was assumed to be at least 8 
mmHg. Right ventricular systolic pressure was therefore calculated as the sum of the right 
atrial pressure and the transtricuspid valve pressure gradient during systole, that is, at least 110 mmHg. In the absence of pulmonic stenosis, this indicated severe pulmonary 
hypertension. Similarly, using the modified Bernoulli equation, peak velocity of pulmonic 
regurgitation (Vmax=4·0 m/s) translated to a pulmonary diastolic pressure of 64 mmHg, which 
also indicates severe pulmonary hypertension. 
 
The underlying aetiology of the vasculitis in this patient remains unknown. The optimal 
treatment of PAH ideally involves identification of the underlying cause. If the aetiology 
cannot be identified and removed before permanent remodelling of the pulmonary 
vasculature has occurred, the prognosis for recovery is grave. In cases where the underlying 
cause is unknown or cannot be controlled, the primary aim of therapy is to reduce the 
pulmonary vascular resistance and right ventricular afterload. In human patients, various 
drugs are advocated for the treatment of primary pulmonary hypertension and pulmonary 
hypertension where the underlying causes are either unidentified or untreatable; 
recommended treatments include oxygen supplementation, anticoagulation, calcium channel 
blockers, prostacyclin, prostacyclin analogues, endothelin receptor antagonists, 
phosphodiesterase inhibitors and ultimately lung transplantation (Runo and Loyd 2003, 
Badesch and others 2004). A number of these strategies have been tried in canine patients. 
 
Nitric oxide is critical in pulmonary vascular homeostasis and is synthesised by nitric oxide 
synthetase (NOS) from l-arginine. Expression of NOS in PAH is variable, suggesting a multi-
factorial mechanism and dysfunction of NOS (Giaid and Saleh 1995, Xue and Johns 1995, 
Tuder and others 1999). Millatt and others (2003) observed increased lung concentrations of 
asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS, with concurrently 
increased NOS expression in a murine model of chronic hypoxia-induced PAH. They hypothesised that the increase in ADMA might be related to a dysregulation of 
dimethylarginine dimethylaminohydrolase, the enzyme that metabolises ADMA. This 
hypothesis is supported by reports of improvement in pulmonary artery pressures and 
haemodynamics in human beings with PAH supplemented with l-arginine (McCaffrey and 
others 1995, Mehta and others 1995, Nagaya and others 2001). In addition to oxygen, 
inhalant NO gas has been advocated as the most effective and specific therapy for primary 
PAH in people (Rubin 1997). Gene transfer of NOS has successfully reduced pulmonary 
pressures in animal models and is a potential future treatment (Champion and others 2002). 
 
Sildenafil, vardenafil and tadalafil are selective type V phosphodiesterase inhibitors that 
augment the action of endogenous NO in vitro. Sildenafil reduces pulmonary pressures and 
improves symptoms in people with PAH (Ghofrani and others 2002, Wilkens and others 
2001). Encouraging results for the use of sildenafil in dogs with PAH have recently emerged; 
however, controlled clinical trials are lacking (Bach and others 2006). 
 
It was thought that verapamil, a calcium channel antagonist, might be beneficial by 
controlling the SVT and improving pulmonary haemodynamics. Differentiation of sinus 
tachycardia from SVT was not achieved with a vagal manoeuvre or precordial thump. The 
tachycardia in the described patient may have been appropriate for the degree of heart failure. 
Therefore, administering verapamil and reducing the heart rate without treating the 
underlying PAH possibly contributed to this patient’s negative outcome. Similarly, frusemide 
diuresis may have contributed to this patient’s already compromised left ventricular preload 
and systemic hypotension. References 
Atkins, C. E., Keene, B. W. & McGuirk, S. M. (1988) Pathophysiologic mechanism of 
cardiac dysfunction in experimentally induced heartworm caval syndrome in dogs: an 
echocardiographic study. American Journal of Veterinary Research 49, 403-410 
Bach, J. F., Rozanski, E. A., MacGregor, J., Betkowski, J. M. & Rush, J. E. (2006) 
Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. 
Journal of Veterinary Internal Medicine 20, 1132-1135 
Badertscher, R. R. IInd, Losonsky, J. M., Paul, A. J. & Kneller, S. K. (1988) Two-
dimensional echocardiography for diagnosis of dirofilariasis in nine dogs. Journal of 
American Veterinary Medical Association 193, 843-846 
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G. & 
McLaughlin, V. V. (2004) Medical therapy for pulmonary arterial hypertension – ACCP 
evidence-based clinical practice guidelines. Chest 126, 35s-62s 
Carpenter, J. L., Moore, F. M. & Albert, D. M. (1988) Polyarteritis nodosa and rheumatic 
heart disease in a dog. Journal of American Veterinary Medical Association 192, 929-932 
Caswell, J. L. & Nykamp, S. G. (2003) Intradural vasculitis and hemorrhage in full sibling 
Welsh springer spaniels. The Canadian Veterinary Journal 44, 137-139 
Champion, H. C., Bivalacqua, T. J., Greenberg, S. S., Giles, T. D., Hyman, A. L. & 
Kadowitz, P. J. (2002) Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) 
partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proceedings of 
the National Academy of Sciences of the United States of America 99, 13248-13253 
Fox, P. R., Petrie, J. P. & Hohenhaus, A. E. (2005) Peripheral vascular disease. In: Textbook 
of Veterinary Internal Medicine, Diseases of the Dog and Cat. 6th edn. Eds S. J.Ettinger and 
E. C.Feldman. Elsevier Saunders, St Louis, MO, USA. pp 1145-1165 
Gavaghan, B. J., Lapointe, J. M. & Thomas, W. P. (1998) Acute onset of pulmonary 
necrotising arteritis in a dog with a left-to-right patent ductus arteriosus. Australian 
Veterinary Journal 76, 786-791 
Ghofrani, H. A., Wiedemann, R., Rose, F., Olschewski, H., Schermuly, R. T., Weissmann, 
N., Seeger, W. & Grimminger, F. (2002) Combination therapy with oral sildenafil and 
inhaled iloprost for severe pulmonary hypertension. Annals of Internal Medicine 136, 515-
522 
Giaid, A. & Saleh, D. (1995) Reduced expression of endothelial nitric oxide synthase in the 
lungs of patients with pulmonary hypertension. The New England Journal of Medicine 333, 
214-221 Goldstein, R. A. (1985) Pulmonary hypertension. A common but often overlooked condition. 
Postgraduate Medicine 78, 109-114 
Heath, D. & Edwards, J. (1958) The pathology of hypertensive pulmonary vascular disease. 
Circulation 18, 533-537 
Humbert, M., Sitbon, O. & Simonneau, G. (2004) Drug therapy: treatment of pulmonary 
arterial hypertension. The New England Journal of Medicine 351, 1425-1436 
Keenan, K. P., Buhles, W. C. Jr, Huxsoll, D. L., Williams, R. G. & Hildebrandt, P. K. (1977) 
Studies on the pathogenesis of Rickettsia rickettsii in the dog: clinical and clinicopathologic 
changes of experimental infection. American Journal of Veterinary Research 38, 851-856 
Kelly, D. F., Grunsell, C. S. & Kenyon, C. J. (1973) Polyarteritis in the dog: a case report. 
The Veterinary Record 92, 363-366 
Kolm, U. S., Amberger, N., Boujon, C. E. & Lombard, C. W. (2004) Plexogenic pulmonary 
arteriopathy in a Pembroke Welsh corgi. The Journal of Small Animal Practice 45, 461-466 
Lewis, R. M. & Borel, Y. (1971) Canine rheumatoid arthritis; a case report. Arthritis and 
Rheumatism 14, 67-74 
Lombard, C. W. & Buergelt, C. D. (1983) Echocardiographic and clinical findings in dogs 
with heartworm-induced cor pulmonale. Compendium (Yardley, PA) 5, 971-980 
McCaffrey, M. J., Bose, C. L., Reiter, P. D. & Stiles, A. D. (1995) Effect of L-arginine 
infusion on infants with persistent pulmonary hypertension of the newborn. Biology of the 
Neonate 67, 240-243 
Mehta, S., Stewart, D. J., Langleben, D. & Levy, R. D. (1995) Short-term pulmonary 
vasodilation with L-arginine in pulmonary hypertension. Circulation 92, 1539-1545 
Meric, S. M., Child, G. & Higgins, R. J. (1986) Necrotizing vasculitis of the spinal 
pachyleptomeningeal arteries in three Bernese mountain dog litter-mates. Journal of 
American Animal Hospital Association 22, 459-465 
Millatt, L. J., Whitley, G. S., Li, D., Leiper, J. M., Siragy, H. M., Carey, R. M. & Johns, R. A. 
(2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic 
hypoxia-induced pulmonary hypertension. Circulation 108, 1493-1498 
Nagaya, N., Uematsu, M., Oya, H., Sato, N., Sakamaki, F., Kyotani, S., Ueno, K., Nakanishi, 
N., Yamagishi, M. & Miyatake, K. (2001) Short-term oral administration of L-arginine 
improves hemodynamics and exercise capacity in patients with precapillary pulmonary 
hypertension. American Journal of Respiratory Critical Care Medicine 163, 887-891 
Perry, L. A., Dillon, A. R. & Bowers, T. L. (1991) Pulmonary Hypertension. Compendium of 
Continuing Education for the Practicing Veterinarian 13, 226-233 Pumarola, M., Brevik, L., Badiola, J., Vargas, A., Domingo, M. & Ferrer, L. (1991) Canine 
leishmaniasis associated with systemic vasculitis in two dogs. Journal of Comparative 
Pathology 105, 279-286 
Rubin, L. J. (1997) Primary pulmonary hypertension. The New England Journal of Medicine 
336, 111-117 
Runo, J. R. & Loyd, J. E. (2003) Primary pulmonary hypertension. Lancet 361, 1533-1544 
Schober, K. E. & Baade, H. (2006) Doppler echocardiographic prediction of pulmonary 
hypertension in West Highland white terriers with chronic pulmonary disease. Journal of 
Veterinary Internal Medicine 20, 912-920 
Schoen, F. J. & Cotran, R. S. (1999) Blood vessels. Chapter 12. In: Robbins Pathologic Basis 
of Disease. 6 edn. Eds R.Cotran, V.Kumer and T.Collins. Elsevier Saunders, Philadelphia, 
PA, USA. pp 493–541 
Scott, D. W., MacDonald, J. M. & Schultz, R. D. (1978) Staphylococcal hypersensitivity in 
the dog. Journal of American Animal Hospital Association 14, 766-779 
Scott-Moncrieff, J. C., Snyder, P. W., Glickman, L. T., Davis, E. L. & Felsburg, P. J. (1992) 
Systemic necrotizing vasculitis in nine young beagles. Journal of American Veterinary 
Medical Association 201, 1553-1558 
Snyder, P. W., Kazacos, E. A., Scott-Moncrieff, J. C., HogenEsch, H., Carlton, W. W., 
Glickman, L. T. & Felsburg, P. J. (1995) Pathologic features of naturally occurring juvenile 
polyarteritis in beagle dogs. Veterinary Pathology 32, 337-345 
Tuder, R. M., Cool, C. D., Geraci, M. W., Wang, J., Abman, S. H., Wright, L., Badesch, D. & 
Voelkel, N. F. (1999) Prostacyclin synthase expression is decreased in lungs from patients 
with severe pulmonary hypertension. American Journal of Respiratory Critical Care 
Medicine 159, 1925-1932 
Turk, J. R., Miller, L. M., Miller, J. B. & Sande, R. D. (1981) Necrotizing pulmonary arteritis 
in a dog with patent ductus arteriosus. The Journal of Small Animal Practice 22, 603-608 
Turk, M. A. M., Turk, J. R., Rantanen, N. W. & Bond, B. R. (1984) Necrotizing pulmonary 
arteritis in a dog with peritoneo-pericardial diaphragmatic hernia. The Journal of Small 
Animal Practice 25, 25-30 
Wilcock, B. P. & Yager, J. A. (1986) Focal cutaneous vasculitis and alopecia at sites of rabies 
vaccination in dogs. Journal of American Veterinary Medical Association 188, 1174-1177 
Wilkens, H., Guth, A., Konig, J., Forestier, N., Cremers, B., Hennen, B., Bohm, M. & 
Sybrecht, G. W. (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary 
pulmonary hypertension. Circulation 104, 1218-1222 Wong, J., Reddy, V. M., Hendricks-Munoz, K., Liddicoat, J. R., Gerrets, R. & Fieman, J. R. 
(1995) Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and 
increased pulmonary blood flow. The American Journal of Physiology 269, H1965-H1972 
Xue, C. & Johns, R. A. (1995) Endothelial nitric oxide synthase in the lungs of patients with 
















 Figure 1. Lateral (A) and dorsoventral (B) thoracic radiographs. Marked right atrial and 
ventricular enlargement (large arrows), with dorsal tracheal displacement (small arrows) and 
dilated pulmonary arteries (arrow heads) 
 
 Figure 2. Six-lead electrocardiogram, 50 mm/s, 1 mV=10 mm. A rapid supraventricular 
rhythm is present with deep S waves in leads I, II, II and aVF, tall R wave in lead III and a 









 Figure 3. Two-dimensional, M-mode and Doppler echocardiogram. (A) Right four-chamber 
view. Severe dilatation of the right atrium (RA) and right ventricle (RV) are present. The left 
atrium (LA) and left ventricle (LV) are markedly reduced in size. Paradoxical septal motion 
is depicted by the leftward deviation of interventricular septum bulging into the left ventricle. 
(B) Two-dimensional and M-mode echocardiogram, right parasternal short axis view. Note 
the marked right ventricular (RV) dilatation outlined by the right ventricular free wall 
(RVFW) and interventricular septum (IVS). The left ventricle diameter is markedly reduced 
and paradoxical IVS motion is evidenced by the leftward deviation during diastole. LVFW 
left ventricular free wall. (C) Two-dimensional echocardiogram, right parasternal short axis 
of the heart base. Marked dilatation of the main pulmonary artery (MPA), left pulmonary 
artery (LPA) and right pulmonary artery (RPA) is present. Ao, aorta; RVOT, right ventricular 
outflow tract; LA, left atrium; PV, pulmonary valve. (D) Two-dimensional and spectral 
continuous wave Doppler interrogation of the tricuspid valve from the left caudal parasternal 
location. Turbulence is present in the right atrium (RA) because of marked tricuspid 
regurgitation. The transtricuspid jet peak velocity is 5·05 m/s. This represents a transtricuspid 
pressure gradient of 102 mmHg, indicative of severe pulmonary hypertension 
 
 
 Figure 4. Histopathology of the lung (A) and pulmonary vasculature (B and C). (A) 400× 
magnification of the lung (Martius scarlet blue stain) depicts abundant alveolar fibrin exudate 
(stained red). Collagen stains blue and erythrocytes appear yellow-green in colour. (B) ×400 
magnification (H&E) cross-section containing a medium-sized pulmonary artery. Widespread 
nuclear debris throughout the arterial wall with moderate mixed inflammatory cellular 
infiltrate in the surrounding elastic laminae connective tissue. (C) ×400 magnification of a 
small pulmonary artery (Martius scarlet blue). Fibrinoid necrosis exhibited by circumferential 
red stain in the arterial wall with prominent perivascular inflammation. 
 